Niraparib maintenance has a tolerable safety profile in patients with ovarian cancer, with hematologic toxicities being “the primary concern,” according to researchers. They evaluated the safety of ...

Tesaro’s niraparib has been approved as a maintenance therapy for ovarian cancer in the US, although the company experienced a setback in its bid to develop the drug in breast cancer after ...

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer.

GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in the treatment of advanced ovarian cancer. The U.K. drugmaker said that ...